The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

valentis.com

Founded Year

1992

Stage

PIPE - IV | IPO

About Valentis

Formerly GeneMedicine, Inc.; merged with Megabios in 1999, became Valentis.

Valentis Headquarter Location

533 Airport Boulevard Suite 400

Burlingame, California, 94010,

United States

650-697-1900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Valentis News

News: Valentis Announces New Vice President of Strategy, Martha Hunter | CitizenWire

Mar 5, 2021

| CitizenWire PITTSBURGH, Pa. /CitizenWire/ -- Valentis today announced that Martha Hunter will become the company's first-ever Vice President of Strategy, effective March 2021. She fills a new position helping the company meet growing demand for expansion. Valentis is committed to an aggressive plan that focuses on messaging and education to advance its security solution, supply chain, and risk management consulting services worldwide. Martha Hunter comes from the marketing industry where she was a Business Development Executive for six years. Hunter's new position will be responsible for developing and implementing the strategic growth initiatives for Valentis using her experience and resolve to meet objectives to Valentis. "Valentis already has a reputation for breaking the mold in the security and investigations industry. I have spent my career challenging people and companies to think differently and ask the question 'Why not us? Valentis's culture, values and leadership style embodies that spirit," says V.P. of Strategy Hunter. She adds, "Strategy development is not a once-a-year thing anymore, it's ongoing and needs to come with recommendations and actions and the company needs to be willing to act. I'm honored to have the opportunity to play a role in the execution piece of strategy, and I'm thrilled to join a women-owned, purpose driven company and look forward to driving new possibilities for our people, our customers and our stakeholders." Marnie Sutch, CEO, of Valentis welcomed Martha to her new position, stating, "The addition of Martha to our team is about her ability to bring innovation and change to Valentis. The ability to deliver a professional service that delivers a driven result for our clients is a team effort and having Martha strengthens our team." About Valentis: Valentis is a fully operational security logistics and risk management solution for a variety of clients and security concerns. We are growing domestically, and envision global ventures, with services and products under development to create a network of global affiliates, lead through branding, and expand our clients; financial institutions, governments, religious facilities, maritime, cybersecurity, combined with specially developed training, software and telecommunication consultancy, and more. We are mindful and committed and care about our clients, team, and shareholders. More information:

Valentis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Valentis Rank

  • When was Valentis founded?

    Valentis was founded in 1992.

  • Where is Valentis's headquarters?

    Valentis's headquarters is located at 533 Airport Boulevard, Burlingame.

  • What is Valentis's latest funding round?

    Valentis's latest funding round is PIPE - IV.

  • Who are the investors of Valentis?

    Investors of Valentis include TZP Group, Summer Street Capital Partners and Brantley Partners.

  • Who are Valentis's competitors?

    Competitors of Valentis include Soleno Therapeutics, Vitae Pharmaceuticals, BioCardia, Creative Biomolecules, Advanced Biohealing and 11 more.

You May Also Like

R
Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

N
Neuronyx

Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.

H
Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

Immunomic Therapeutics Logo
Immunomic Therapeutics

Immunomic Therapeutics operates as a development-stage biotechnology company. The Company develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets.

M
Medicorp Technologies

Medicorp Technologies Ltd. (now merged into Matrix Laboratories) is a manufacturer of bulk drugs, including the popular Acyclovir. It also manufactures anti-viral, anti-fungal, anti-ulcer and cardiac drugs. Medicorp's core competency lies in the anti-infective, central nervous system and cardiovascular therapeutic segments. Sensing synergies between Matrix Laboratories and Medicorp in the manufacture of bulk drugs, Medicorp merged into Matrix labs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.